Cullinan Therapeutics (CGEM) Competitors $9.01 +0.03 (+0.33%) As of 10:48 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. HRMY, KNSA, VCEL, DNLI, CGON, VERA, GMTX, IMCR, GLPG, and AGIOShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), CG Oncology (CGON), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Immunocore (IMCR), Galapagos (GLPG), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. Its Competitors Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Vera Therapeutics Gemini Therapeutics Immunocore Galapagos Agios Pharmaceuticals Cullinan Therapeutics (NASDAQ:CGEM) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking. Does the MarketBeat Community prefer CGEM or HRMY? Harmony Biosciences received 23 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 84.21% of users gave Cullinan Therapeutics an outperform vote while only 72.45% of users gave Harmony Biosciences an outperform vote. CompanyUnderperformOutperformCullinan TherapeuticsOutperform Votes4884.21% Underperform Votes915.79%Harmony BiosciencesOutperform Votes7172.45% Underperform Votes2727.55% Which has higher valuation & earnings, CGEM or HRMY? Harmony Biosciences has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$153.16M-$2.91-3.10Harmony Biosciences$744.85M2.63$128.85M$2.6213.04 Does the media prefer CGEM or HRMY? In the previous week, Harmony Biosciences had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 12 mentions for Harmony Biosciences and 4 mentions for Cullinan Therapeutics. Harmony Biosciences' average media sentiment score of 1.16 beat Cullinan Therapeutics' score of 0.65 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CGEM or HRMY? 86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 7.2% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 23.6% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, CGEM or HRMY? Cullinan Therapeutics has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Do analysts recommend CGEM or HRMY? Cullinan Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 232.96%. Harmony Biosciences has a consensus target price of $53.00, suggesting a potential upside of 55.11%. Given Cullinan Therapeutics' higher probable upside, equities research analysts clearly believe Cullinan Therapeutics is more favorable than Harmony Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Harmony Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is CGEM or HRMY more profitable? Harmony Biosciences has a net margin of 17.98% compared to Cullinan Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 23.16% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -26.54% -25.32% Harmony Biosciences 17.98%23.16%14.24% SummaryHarmony Biosciences beats Cullinan Therapeutics on 15 of the 18 factors compared between the two stocks. Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$531.73M$3.10B$5.60B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-3.1733.2727.2320.02Price / SalesN/A468.94417.65154.33Price / CashN/A168.6838.2534.64Price / Book0.853.447.124.70Net Income-$153.16M-$72.35M$3.23B$247.97M7 Day Performance3.09%7.57%2.74%2.64%1 Month Performance13.91%18.09%8.94%6.39%1 Year Performance-58.50%-16.71%31.59%13.95% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics1.6968 of 5 stars$9.01+0.3%$30.00+233.0%-61.4%$531.73MN/A-3.1730Analyst ForecastHRMYHarmony Biosciences4.7782 of 5 stars$35.56+3.1%$53.00+49.0%+18.4%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2592 of 5 stars$27.92+2.0%$38.80+39.0%+61.1%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.6777 of 5 stars$40.46-2.0%$61.14+51.1%+2.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.354 of 5 stars$13.96+5.4%$33.71+141.5%-29.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.5187 of 5 stars$26.59+3.8%$58.22+119.0%-25.6%$2.03B$662K-17.6161Positive NewsAnalyst RevisionVERAVera Therapeutics2.9091 of 5 stars$31.74+67.5%$65.00+104.8%-42.5%$2.02BN/A-12.1640Short Interest ↑Analyst RevisionHigh Trading VolumeGMTXGemini TherapeuticsN/A$46.68-0.4%N/A+33.6%$2.02BN/A-46.6830High Trading VolumeIMCRImmunocore3.0627 of 5 stars$38.65+5.6%$58.89+52.4%-13.5%$1.94B$333.58M-40.68320Analyst RevisionHigh Trading VolumeGLPGGalapagos0.404 of 5 stars$29.20+1.5%$25.33-13.2%+8.2%$1.92B$288.19M0.001,310Positive NewsAGIOAgios Pharmaceuticals4.1274 of 5 stars$32.63+1.7%$56.00+71.6%-27.6%$1.89B$37.04M2.88390Positive NewsAnalyst Revision Related Companies and Tools Related Companies HRMY Alternatives KNSA Alternatives VCEL Alternatives DNLI Alternatives CGON Alternatives VERA Alternatives GMTX Alternatives IMCR Alternatives GLPG Alternatives AGIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGEM Stock Free CGEM Stock Alerts